Qiagen and Celera establish distribution agreement for respiratory pathogen panel
Qiagen and Celera have announced an agreement under which Qiagen will distribute a Celera molecular multiplex assay. The assay is the next generation version of Qiagen’s ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of different pathogens in a single run.
Under the terms of the agreement, Qiagen has the exclusive worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The ResPlex assay detects 19 different pathogens associated with respiratory infections and is designed for use with LiquiChip (Luminex) 100 and 200 instrument platforms.
The new ResPlex kits will be available through Qiagen’s existing sales channels. The new test will be submitted for regulatory approval in the United States and Europe.
AI.gov.au launches to help safe and responsible AI use
Providing guidance, tools and resources to help Australian businesses use AI safely, the...
AusBiotech responds to Budget 2026–27
The life sciences industry body has responded to measures set out in the Australian...
$6.2m for nine science projects involving Japan and neighbours
Investments under the Global Science and Technology Diplomacy Fund will support nine...
